Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lateral group

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    135 result(s) found for: Lateral group. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2007-002117-39 Sponsor Protocol Number: MEDALS Start Date*: 2008-01-31
    Sponsor Name:Jorge Matias-Guiu Guia
    Full Title: MEMANTINA (Ebixa X) PARA LA DISCAPACIDAD FUNCIONAL EN LA ESCLEROSIS LATERAL AMIOTRÓFICA MEMANTINE (Ebixa R) FOR FUNCTIONAL DISABILITY IN AMYOTROPHIC LATERAL SCLEROSIS .
    Medical condition: Esclerosis Lateral Amiotrofica Amyotrophic lateral Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002026 Amyotrophic lateral sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-007320-25 Sponsor Protocol Number: TRO19622 CL E Q 1015-1 Start Date*: 2009-06-24
    Sponsor Name:TROPHOS SA
    Full Title: Phase II/III, multicenter, randomized, parallel group,double-blind, placebo controlled study to assess safety and efficacy of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) patients treated with r...
    Medical condition: ALS is a fatal neuromuscular disorder causing progressive loss of nervous control of voluntary muscles because of destruction of motor neurons in the brain and spinal cord.Riluzole is the only appr...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002026 Amyotrophic lateral sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) GB (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-000352-36 Sponsor Protocol Number: HP-ALS-TIA Start Date*: 2020-04-27
    Sponsor Name:Christoffer Laustsen
    Full Title: MRI of neurometabolic impairment in ALS and TIA using hyperpolarized pyruvate
    Medical condition: Amyotrophic lateral sclerosis Transient ischemic attack
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-002110-22 Sponsor Protocol Number: LTA-2-2008 Start Date*: 2008-09-16
    Sponsor Name:Prof. dr L.H. van den Berg, UMC-Utrecht
    Full Title: A randomised sequential trial of Lithium in amyotrophic lateral sclerosis
    Medical condition: Amyotrophic lateral sclerosis (ALS) is a disease characterised by progressive degeneration of motor neurons in brain and spinal cord leading to muscle weakness. ALS can occur at anytime in adulthoo...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052889 ALS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2006-002660-26 Sponsor Protocol Number: ONO-2506POE014 Start Date*: 2007-01-08
    Sponsor Name:ONO Pharmaceutical Co.,Ltd
    Full Title: A MULTI-CENTRE,RANDOMISED,DOUBLE BLIND,PLACEBO CONTROLLED,PARALLEL GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ONO-2506PO COMPARED TO PLACEBO,IN THE PRESENCE OF RILUZOLE,TO PATIENTS DIAGNOSED...
    Medical condition: Amyotrophic Lateral Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10002026 Amyotrophic lateral sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) BE (Completed) FR (Completed) AT (Prematurely Ended) IT (Prematurely Ended) NL (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-001094-15 Sponsor Protocol Number: LitALS Start Date*: 2008-03-10
    Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO"
    Full Title: SINGLE-BLIND, RANDOMIZED, PARALLEL GROUP, DOSE-FINDING TRIAL ON LITHIUM FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
    Medical condition: ALS patient according with the El-Escorial criteria
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002026 Amyotrophic lateral sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001688-49 Sponsor Protocol Number: ALS-GA-201 Start Date*: 2006-08-14
    Sponsor Name:TEVA Pharmaceutical Industries. Ltd.
    Full Title: A multi-national, multi-centre, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, tolerability and safety of 40 mg glatiramer acetate injection in subjects ...
    Medical condition: Early stage of amyotrophic lateral sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10002026 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004619-30 Sponsor Protocol Number: ALXN1210-ALS-308 Start Date*: 2020-09-14
    Sponsor Name:Alexion Pharmaceuticals
    Full Title: A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotroph...
    Medical condition: Amyotrophic Lateral Sclerosis (ALS), motor neuron disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) SE (Prematurely Ended) GB (GB - no longer in EU/EEA) DE (Prematurely Ended) DK (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) BE (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-002855-15 Sponsor Protocol Number: CTCH346A2211E1 Start Date*: 2004-12-29
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A long-term extension to a randomized, double-blind, placebo-controlled, stratified, parallel-group, multicenter, dose-ranging study evaluating four oral doses of TCH346 (1.0, 2.5, 7.5 and 15mg) ad...
    Medical condition: Amyotrophic Lateral Sclerosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004040-29 Sponsor Protocol Number: CY5031 Start Date*: Information not available in EudraCT
    Sponsor Name:Cytokinetics Inc
    Full Title: A Phase 3, Multi-center, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Reldesemtiv in Patients with Amyotrophic Lateral Sclerosis (ALS).
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IE (Prematurely Ended) FR (Prematurely Ended) PT (Prematurely Ended) BE (Prematurely Ended) SE (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended) NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-024423-24 Sponsor Protocol Number: AB10015 Start Date*: 2013-01-29
    Sponsor Name:ABScience
    Full Title: A prospective, multicenter, randomized, double-blind, placebocontrolled, parallel group, phase 2 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients su...
    Medical condition: patients suffering from Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GR (Completed) SK (Prohibited by CA) IT (Completed) HU (Completed) PT (Completed) IE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-004727-33 Sponsor Protocol Number: CY5032 Start Date*: 2022-10-28
    Sponsor Name:Cytokinetics Inc
    Full Title: A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) BE (Completed) NL (Prematurely Ended) SE (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended) PT (Ongoing) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004171-12 Sponsor Protocol Number: ALSTEM Start Date*: 2020-07-22
    Sponsor Name:Polski Bank Komórek Macierzystych JSC (PBKM)
    Full Title: The evaluation of the effect of Wharton’s Jelly Mesenchymal Stem Cells (WJMSCs) on the immune system of patients with Amyotrophic Lateral Sclerosis (ALS)
    Medical condition: Amyotrophic Lateral Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003962-38 Sponsor Protocol Number: RT001-014 Start Date*: 2021-02-02
    Sponsor Name:Retrotope, Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO ASSESS EFFICACY, LONG TERM SAFETY AND TOLERABILITY OF RT001 IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS
    Medical condition: Amyotrophic Lateral Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) SE (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005413-23 Sponsor Protocol Number: CY4031 Start Date*: 2016-05-20
    Sponsor Name:Cytokinetics, Inc.
    Full Title: A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tirasemtiv in Patients with Amyotroph...
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) IE (Completed) NL (Completed) ES (Completed) PT (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-003479-20 Sponsor Protocol Number: 2011/433 Start Date*: 2013-04-15
    Sponsor Name:Handkirurgiska kliniken, Universitetssjukhuset Örebro
    Full Title: Lateral humerus epicondylitis- a clinical, muscle morpological, muscle metabolical and functional evaluation of a new model for treatment.
    Medical condition: Chronic lateral humerus epiconcylitis
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004863 10024032 Lateral epicondylitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001431-20 Sponsor Protocol Number: CHDR1417 Start Date*: 2015-08-17
    Sponsor Name:Centre for Human Drug Research
    Full Title: A randomized, double blind, double-dummy placebo controlled, 3-way cross-over study to determine the test-retest reliability of, and the effect of oral retigabine and riluzole on, peripheral motor ...
    Medical condition: Amytrophic Lateral Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-021936-33 Sponsor Protocol Number: RD.03.SPR.40131 Start Date*: 2011-01-28
    Sponsor Name:Galderma R&D SNC
    Full Title: A multi-center randomized, double-blind, placebo controlled, parallel-group study of CD 07743 for the improvement of Lateral Canthal Lines (crow’s feet)
    Medical condition: Moderate to severe Lateral Canthal Lines
    Disease: Version SOC Term Classification Code Term Level
    12.1 10052609 Glabellar frown lines LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005971-11 Sponsor Protocol Number: AP101-02 Start Date*: 2021-10-20
    Sponsor Name:AL-S Pharma, AG
    Full Title: A Phase 2a, multicenter, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, pharmacodynamic markers, and pharmacokinetics of AP-101 in patients with familial amyot...
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) DE (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-002062-62 Sponsor Protocol Number: ALS-TAL-201 Start Date*: 2008-10-14
    Sponsor Name:Teva Pharmaceutical Industries, Ltd
    Full Title: A Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Tolerability and Safety of talampanel in Subjects with Amyotrophic Lateral S...
    Medical condition: Amyotrophic lateral sclerosis (ALS).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052653 Amyotrophic lateral sclerosis gene carrier PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FR (Completed) ES (Completed) IT (Completed) BE (Completed) HU (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 20:20:23 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA